InspireMD, Inc.
About InspireMD, Inc.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.0M
- Net income
- -$48.8M
- Total assets
- $69.4M
- Market cap
- $41.2M
- Gross margin
- 29.5%
- Operating margin
- -552.6%
- Net margin
- -543.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.0M
- Cost of revenue
- $6.3M
- Gross profit
- $2.6M
- Operating expenses
- $52.3M
- Operating income
- -$49.6M
- Income tax
- $63.0K
- Net income
- -$48.8M
- EPS (basic)
- $-0.76
- EPS (diluted)
- $-0.76
Balance sheet
- Total assets
- $69.4M
- Current assets
- $61.5M
- Total liabilities
- $14.2M
- Current liabilities
- $10.7M
- Shareholders’ equity
- $55.2M
Cash flow
- Operating cash flow
- -$35.1M
- Investing cash flow
- -$30.6M
- Financing cash flow
- $55.6M
- Net cash flow
- -$10.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $41.2M
- EPS (diluted)
- $-0.76
- Shares outstanding
- 52.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 22, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $48.8M in FY2025.
- Revenue grew 100% from FY2021 to FY2025.
- Gross margin of 29.5%, net margin -543.3%.
- Trading 72% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review InspireMD, Inc..
Write a review
News about InspireMD, Inc.
News & sentiment via Polygon.io
